Xeris Biopharma Reports Third Quarter 2022 Financial Results and Recent Events

Achieved record net product revenue of $29.6M – a 17% increase from Q2 ’22, and a 31% increase from same period prior year on a pro forma basis; tightens full-year total net product revenue guidance to $105M-$110M

Ended Q3 with $93.4M in cash, cash equivalents and short-term investments; raises 2022 year-end cash balance guidance from $90M-$110M to $110M-$120M

Remains on track to achieve $50M in synergies by year-end 2022 and cash flow breakeven by year-end 2023

Reported positive topline results from its Phase 1 study of subcutaneous levothyroxine (XP-8121)

Published the longer-term effects of levoketoconazole (Recorlev®) from extended evaluation of SONICS study in ‘European Journal of Endocrinology’

Hosting conference call and webcast today at 8:30 a.m. ET

CHICAGO--()--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the third quarter and nine months ended September 30, 2022 and other corporate highlights.

“Our third quarter and year-to-date performance reflect the continued strength of our growing commercial products coupled with disciplined management of our cash. This gives us confidence to raise our year-end cash balance guidance to $110-$120 million, reaffirm and tighten net product revenue range to $105-110 million for full-year, and reaffirm our guidance of $50 million in synergies and cash flow breakeven by year-end 2023,” said Paul R. Edick, Chairman and CEO of Xeris Biopharma. “As we finish the year and head into 2023, we expect to build upon our 2022 momentum and continue creating shareholder value through continued revenue growth, careful allocation of resources, and prudent expense management.”

Third Quarter Highlights and Recent Events

Commercial Products

  • Gvoke®: Third quarter 2022 net revenue was $13.7 million as compared to $11.0 million in the third quarter of 2021 – an increase of approximately 24%. Gvoke prescriptions topped 38,000 for the first time, growing more than 41% compared to the same period in 2021. Gvoke’s market share of the retail TRx glucagon market grew to approximately 23% at the end of October.
  • Keveyis®: Third quarter net revenue was $13.4 million – an increase of approximately 17% compared to the same period in 2021 on a pro forma basis. The number of patients on Keveyis increased 9% from the same period in 2021.
  • Recorlev®: Third quarter net revenue increased to $2.5 million driven primarily by increases in the number of patients on therapy. Xeris recently announced that the European Journal of Endocrinology (EJE) published the extended evaluation (EE) results of the SONICS study evaluating longer-term effects of levoketoconazole (Recorlev) on cortisol levels, biomarkers of Cushing’s syndrome (CS) comorbidities, clinical signs, and symptoms of CS, and quality of life. The manuscript also reports findings from pituitary adenoma imaging in the SONICS study.

 

Three Months Ended
September 30,

 

Change

 

 

2022

 

2021

 

$

%

 

Product revenue (in thousands):

 

 

 

 

 

 

 

Gvoke

$

13,663

 

$

11,035

 

$

2,628

23.8

 

Keveyis

 

13,371

 

 

 

 

13,371

nm

 

Recorlev

 

2,520

 

 

 

 

2,520

nm

 

Product revenue, net

 

29,554

 

 

11,035

 

 

18,519

167.8

 

Royalty, contract and other revenue

 

171

 

 

25

 

 

146

nm

 

Total revenue

$

29,725

 

$

11,060

 

$

18,665

168.8

 

 

 

 

 

 

 

 

 

Pipeline Programs

  • XeriSol® levothyroxine (XP-8121): In October, Xeris reported positive topline results from its Phase 1 study of XP-8121. The Company has requested a Type C meeting with the FDA and anticipates a response by year-end.

Upcoming Events

  • Xeris will participate at the Jefferies London Healthcare Conference, November 15-17 in London.
  • Xeris will participate at the Piper Sandler 34th Annual Healthcare Conference, November 29-December 1 in New York City

Year-to-Date 2022 Revenue Results

Gvoke®: Net revenue increased by $9.7 million or approximately 35% for the nine months ended September 30, 2022 compared to the same periods ended September 30, 2021, respectively. Gvoke prescriptions grew 59% during the nine months ended September 30, 2022 compared to the same period ended September 30, 2021. The growth in product demand was partially offset by a decrease in net pricing.

Keveyis®: Net revenue was $35.6 million for the nine months ended September 30, 2022, an increase of 19% from the same period ended September 30, 2021 on a pro forma basis. This growth is driven by an increase in patient demand and net pricing.

Recorlev®: Net revenue was $3.6 million for the nine months ended September 30, 2022. The product received FDA approval in December 2021 and was launched for commercialization in January 2022.

 

 

Nine Months Ended
September 30,

 

Change

 

 

2022

 

2021

 

$

 

%

Product revenue (in thousands):

 

 

 

 

 

 

 

Gvoke

 

$

37,595

 

$

27,921

 

$

9,674

34.6

Keveyis

 

 

35,506

 

 

 

 

35,506

nm

Recorlev

 

 

3,623

 

 

 

 

3,623

nm

Product revenue, net

 

 

76,724

 

 

27,921

 

 

48,803

174.8

Royalty, contract and other revenue

 

 

380

 

 

240

 

 

140

58.3

Total revenue

 

$

77,104

 

$

28,161

 

$

48,943

173.8

 

 

 

 

 

 

 

 

Third Quarter and Year-to-Date 2022 Other Results

Cost of goods sold were $5.3 million and $16.3 million for the three and nine months ended September 30, 2022, respectively. The increases were attributable to an increase in sales as well as product mix and increased costs.

Research and development expenses increased $0.4 million or 6.7% for the three months ended September 30, 2022 when compared to the same period in 2021. The increase was primarily driven by clinical services costs.

Research and development expenses increased $0.9 million or 6.2% for the nine months ended September 30, 2022 compared to the same period in 2021. The increase was primarily driven by higher personnel related costs, offset by lower product development costs.

Selling, general and administrative expenses increased $8.0 million and $31.8 million or 30.0% and 44.5% for the three and nine months ended September 30, 2022, respectively, compared to the same periods in 2021. Personnel-related costs increased by $4.6 million and $24.2 million for the three and nine months primarily to support Keveyis, acquired in October 2021, and Recorlev, launched in 2022, as well as an expansion of our endocrinology sales force. Marketing expenses increased by $2.6 million and $4.5 million for the three and nine months primarily to support the launch of Recorlev.

Net Loss for the three months ended September 30, 2022, was $21.8 million, or $0.16 per share, and a net loss of $81.7 million, or $0.60 per share, for the nine months ended September 30, 2022.

Cash, cash equivalents, and short-term investments at September 30, 2022 was $93.4 million compared to $102.4 million at December 31, 2021. Total shares outstanding at October 31, 2022 was 135,985,090.

Conference Call and Webcast Details

Xeris will host a conference call and webcast today, Wednesday, November 9, 2022, at 8:30 a.m. Eastern Time. To pre-register for the conference call please use this link:  https://www.netroadshow.com/events/login?show=6f095f54&confId=42439.  After registering, a confirmation email will be sent, including dial-in details and a unique code for entry.  The Company recommends registering a minimum of ten minutes prior to the start of the call.  Following the conference call, a replay will be available until Wednesday, November 23, 2022, at US:1 929 458 6194, US Toll Free: 1 866 813 9403, UK: 0204 525 0658, Canada: 1 226 828 7578, or all other locations: +44 204 525 0658 Access Code: 057900.  In addition, a live audio of the conference call will be available as a webcast. To join the webcast, please visit “Events” on investor relations page of the Company’s website at www.xerispharma.com or use this link: https://events.q4inc.com/attendee/469998551.

About Xeris

Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.

Xeris Biopharma Holdings is headquartered in Chicago, IL. For more information, visit www.xerispharma.com, or follow us on Twitter, LinkedIn, or Instagram.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Xeris Biopharma Holdings, Inc. including statements regarding the financial outlook for the full-year 2022, including projections regarding year-end 2022 cash estimates and net product revenue, the Company’s expectations regarding its cash flow breakeven projection, estimates and projections about the potential synergies in fiscal year 2022 resulting from the Strongbridge Biopharma acquisition, the market and therapeutic potential of its products and product candidates, expectations regarding clinical data or results from planned clinical trials, the timing of clinical trials, the timing or likelihood of regulatory approval and commercialization of its product candidates, the timing or likelihood of expansion into additional markets, the potential utility of its formulation platforms and other statements containing the words “will,” “would,” “continue,” “expect,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on numerous assumptions and assessments made in light of Xeris’ experience and perception of historical trends, current conditions, business strategies, operating environment, future developments, geopolitical factors and other factors it believes appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements in this communication could cause Xeris’ actual results, performance or achievements, industry results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and persons reading this communication are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as of the date of this communication. Additional information about potential impacts of COVID-19, financial, operational, economic, competitive, regulatory, governmental, technological, and other factors that may affect Xeris is set forth in the "Risk Factors" section of the most recently filed Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, the contents of which are not incorporated by reference into, nor do they form part of, this communication. Any forward-looking statements in this communication are based upon information available to Xeris, as of the date of this communication and, while believed to be true when made, may ultimately prove to be incorrect. Subject to any obligations under applicable law, Xeris does not undertake any obligation to update any forward-looking statement whether as a result of new information, future developments or otherwise, or to conform any forward-looking statement to actual results, future events, or to changes in expectations. All subsequent written and oral forward-looking statements attributable to Xeris or any person acting on behalf of any of them are expressly qualified in their entirety by this paragraph.

XERIS BIOPHARMA HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

 

Three Months Ended
September 30,

 

Nine Months Ended
September 30,

 

2022

 

2021

 

2022

 

2021

Product revenue, net

$

29,554

 

 

$

11,035

 

 

$

76,724

 

 

$

27,921

 

Royalty, contract and other revenue

 

171

 

 

 

25

 

 

 

380

 

 

 

240

 

Total revenue

 

29,725

 

 

 

11,060

 

 

 

77,104

 

 

 

28,161

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of goods sold, excluding amortization of intangible assets

 

5,260

 

 

 

3,220

 

 

 

16,343

 

 

 

8,429

 

Research and development

 

6,043

 

 

 

5,663

 

 

 

16,011

 

 

 

15,078

 

Selling, general and administrative

 

34,491

 

 

 

26,535

 

 

 

103,388

 

 

 

71,539

 

Amortization of intangible assets

 

2,711

 

 

 

 

 

 

8,132

 

 

 

 

Total costs and expenses

 

48,505

 

 

 

35,418

 

 

 

143,874

 

 

 

95,046

 

Loss from operations

 

(18,780

)

 

 

(24,358

)

 

 

(66,770

)

 

 

(66,885

)

Other expense

 

(3,390

)

 

 

(1,651

)

 

 

(16,046

)

 

 

(5,050

)

Net loss before benefit from income taxes

 

(22,170

)

 

 

(26,009

)

 

 

(82,816

)

 

 

(71,935

)

Benefit from income taxes

 

339

 

 

 

 

 

 

1,086

 

 

 

 

Net loss

$

(21,831

)

 

$

(26,009

)

 

$

(81,730

)

 

$

(71,935

)

 

 

 

 

 

 

 

 

Net loss per common share - basic and diluted

$

(0.16

)

 

$

(0.39

)

 

$

(0.60

)

 

$

(1.11

)

 

 

 

 

 

 

 

 

Weighted average common shares outstanding - basic and diluted

 

135,951,761

 

 

 

66,497,593

 

 

 

135,508,203

 

 

 

64,722,552

 

XERIS BIOPHARMA HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

 

September 30, 2022

 

December 31, 2021

 

(unaudited)

 

 

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

84,109

 

$

67,271

Short-term investments

 

9,324

 

 

35,162

Trade accounts receivable, net

 

27,518

 

 

17,456

Inventory

 

20,121

 

 

18,118

Prepaid expenses and other current assets

 

7,847

 

 

4,589

Total current assets

 

148,919

 

 

142,596

Property and equipment, net

 

5,751

 

 

6,627

Goodwill

 

123,318

 

 

131,450

Intangible assets, net

 

22,859

 

 

22,859

Other assets

 

2,170

 

 

829

Total assets

$

303,017

 

$

304,361

Liabilities and Stockholders’ Equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

 

3,916

 

 

8,924

Other accrued liabilities

 

37,707

 

 

49,088

Accrued trade discounts and rebates

 

19,321

 

 

15,041

Accrued returns reserve

 

7,277

 

 

4,000

Other current liabilities

 

337

 

 

1,987

Total current liabilities

 

68,558

 

 

79,040

Long-term debt, net of unamortized debt issuance costs

 

138,507

 

 

88,067

Contingent value rights

 

30,100

 

 

22,531

Supply agreement liability, less current portion

 

 

 

5,991

Deferred rent

 

6,645

 

 

6,883

Deferred tax liabilities

 

3,856

 

 

4,942

Other liabilities

 

311

 

 

1,676

Total liabilities

 

247,977

 

 

209,130

Total stockholders’ equity

 

55,040

 

 

95,231

Total liabilities and stockholders’ equity

$

303,017

 

$

304,361

 

Contacts

Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
312-736-1237

#Hashtags

Contacts

Investor Contact
Allison Wey
Senior Vice President, Investor Relations and Corporate Communications
awey@xerispharma.com
312-736-1237